{
    "title": "Nervecentre - Encounter 1",
    "component": "RawClinicalNote",
    "props": {
        "encounterNumber": 1,
        "date": "2024-03-05",
        "visitType": "Outpatient",
        "provider": "Dr. P. Stevens",
        "specialty": "MRCGP",
        "rawText": "### Nervecentre\n\n**Module:** Laboratory Alerting & Task Management\n**Event Type:** Automated Laboratory Alert \u2013 LFT Derangement \n\n---\n\n#### 1. Alert Event Summary\n\n* **System Alert ID:** NC-LFT-20240305-001\n* **Patient:** Sarah Miller (MRN: SM43850603, DOB: 1981-06-03, Age 43, F) \n* **Linked Encounter:**\n\n  * Visit Type: Outpatient \u2013 General Practice\n  * Date & Time: 2024-03-05 @ 10:15:22 (GMT+01:00)\n  * Clinician: Dr. P. Stevens, MD, MRCGP \n* **Ordering Provider:** Dr. P. Stevens\n* **Requesting Location:** GP Clinic \u2013 Room 3\n\n---\n\n#### 2. Trigger Details\n\n* **Trigger Rule:** Rule ID 4.2 \u2013 *ALT \u2265 1.5 \u00d7 ULN*\n* **Analyte:** Alanine Aminotransferase (ALT)\n* **Result:** 78 U/L (ULN: 40 U/L; 1.95 \u00d7 ULN) \n* **Associated LFTs at Time of Alert:** \n\n  * AST: 55 U/L (H, <35)\n  * ALP: 105 U/L (N, 30\u2013130)\n  * Bilirubin (Total): 12 \u03bcmol/L (N, <21)\n  * INR: 1.0 (N, 0.8\u20131.2)\n  * Platelets: 250 \u00d7 10\u2079/L (N, 150\u2013400)\n* **Pattern of Injury:** Hepatocellular (AST/ALT ratio \u2248 0.7; no cholestasis)\n* **Alert Level:** Level 2 \u2013 Non-Critical, Mandatory Acknowledgment within 72 hours\n* **Severity Banding (System):**\n\n  * ALT 1.5\u20133 \u00d7 ULN \u2192 *Moderate Elevation*\n  * Bilirubin normal, INR normal \u2192 *No acute liver failure criteria*\n\n---\n\n#### 3. Distribution & Delivery Log\n\n* **Primary Recipient:**\n\n  * Dr. P. Stevens (Responsible GP / LFT Ordering Clinician)\n* **Secondary Visibility:**\n\n  * GP Practice LFT Review Pool (Monitoring queue, \u201cGP-LFT-MONITOR\u201d)\n* **Delivery Channels:**\n\n  * Nervecentre mobile app push notification to Dr. Stevens\n  * Medilogik Inbox message (flagged \u2018LFT abnormal \u2013 review required\u2019)\n  * Alert icon added to Sarah Miller\u2019s digital chart (LFT flag)\n\n**Delivery Timeline:**\n\n1. **2024-03-05 10:17:02** \u2013 LFT panel verified in LIS; HL7 message received by Nervecentre.\n2. **2024-03-05 10:17:10** \u2013 Rule ID 4.2 fired (ALT 78 U/L \u2265 1.5 \u00d7 ULN).\n3. **2024-03-05 10:17:15** \u2013 Level 2 alert created and queued.\n4. **2024-03-05 10:17:20** \u2013 Push notification sent to Dr. Stevens\u2019 device and Medilogik Inbox.\n5. **2024-03-05 10:17:25** \u2013 Chart flag updated (amber LFT icon).\n\n---\n\n#### 4. Acknowledgment & Escalation Logic\n\n* **Acknowledgment Requirement:**\n\n  * Alert must be electronically acknowledged by the responsible clinician **within 72 hours** of creation.\n\n* **Current Status:**\n\n  * Acknowledgement: **Pending**\n  * Last System Check: 2024-03-05 18:00 \u2013 *No user interaction recorded.*\n\n* **Scheduled Reminders:**\n\n  * **+24 hours (2024-03-06 10:17)** \u2013 In-app reminder to Dr. Stevens (planned).\n  * **+48 hours (2024-03-07 10:17)** \u2013 Second reminder and addition to GP practice \u201cUnacknowledged LFT\u201d dashboard (planned).\n  * **+72 hours (2024-03-08 10:17)** \u2013 If still unacknowledged, auto-escalate to:\n\n    * GP Duty Doctor / Clinical Lead inbox\n    * Practice admin queue: \u201cFollow-up abnormal results \u2013 contact clinician\u201d.\n\n* **Escalation Rule:**\n\n  * Rule ID 7.1 \u2013 *Unacknowledged Level 2 lab alert >72 h \u2192 escalate to on-call / clinical lead.*\n\n---\n\n#### 5. Linked Tasks (Automatic)\n\n1. **Task ID:** NC-TASK-20240305-ALT-REVIEW\n\n   * **Title:** Review abnormal LFT (ALT 78 U/L) and document plan.\n   * **Owner:** Dr. P. Stevens\n   * **Priority:** Medium\n   * **Due Date/Time:** 2024-03-08 10:15 (72h from encounter)\n   * **Completion Status:** Open\n   * **Task Notes (Pre-populated):**\n\n     * \u201cALT 78 U/L (~1.95 \u00d7 ULN), hepatocellular pattern, no bilirubin or INR derangement. Consider MASLD, NSAID use, and DMARD candidacy (planned MTX). Document clinical correlation, repeat LFT interval, and DMARD decision.\u201d\n\n2. **Task ID:** NC-TASK-20240305-MASLD-COUNSEL\n\n   * **Title:** Confirm lifestyle counselling & weight-loss plan for suspected MASLD.\n   * **Owner:** GP Practice Nurse / Health Coach (Pool: \u2018MASLD-COACH\u2019)\n   * **Priority:** Low\n   * **Due Date/Time:** 2024-03-19 09:00\n   * **Status:** Open\n\n---\n\n#### 6. Safety & Governance Notes\n\n* **Protocol Reference:**\n\n  * Local GP LFT Policy v3.1 \u2013 \u201cAny ALT \u2265 1.5 \u00d7 ULN requires documented review and repeat LFT within 3\u20136 months, sooner if planning hepatotoxic medication (e.g., Methotrexate).\u201d\n* **Clinical Risk Comment (System):**\n\n  * Flag added: \u201cPlanned DMARD (MTX) \u2013 ensure LFT trend and chronic liver disease screen BEFORE initiation.\u201d\n* **Audit Trail (Extract):**\n\n  * 2024-03-05 10:17 \u2013 Alert generated automatically (System).\n  * 2024-03-05 10:17 \u2013 Delivery confirmed to device \u2018STEVENS_GP_IPHONE\u2019.\n  * 2024-03-05 10:18 \u2013 Chart flag updated (System).\n  * *No user acknowledgment recorded yet.*\n\n",
        "dataSource": "Nervecentre"
    },
    "highlights": [
        {
            "text": "Rule ID 4.2 \u2013 *ALT \u2265 1.5 \u00d7 ULN*",
            "color": "yellow"
        },
        {
            "text": "Result: 78 U/L (ULN: 40 U/L; 1.95 \u00d7 ULN)",
            "color": "yellow"
        },
        {
            "text": "AST: 55 U/L (H, <35)",
            "color": "yellow"
        },
        {
            "text": "Severity Banding (System):",
            "color": "yellow"
        },
        {
            "text": "ALT 1.5\u20133 \u00d7 ULN \u2192 *Moderate Elevation*",
            "color": "yellow"
        },
        {
            "text": "Local GP LFT Policy v3.1 \u2013 \u201cAny ALT \u2265 1.5 \u00d7 ULN requires documented review and repeat LFT within 3\u20136 months, sooner if planning hepatotoxic medication (e.g., Methotrexate).\u201d",
            "color": "yellow"
        },
        {
            "text": "Planned DMARD (MTX) \u2013 ensure LFT trend and chronic liver disease screen BEFORE initiation.\u201d",
            "color": "yellow"
        }
    ]
}